Comparative Effects Of Statins Research Articles

Efficacy of statin treatment based on cardiovascular outcomes in elderly patients: a standard meta-analysis and Bayesian network analysis.

ObjectiveStatins have been shown to be beneficial for the prevention of cardiovascular events. In elderly individuals, the efficacy of statins remains controversial and the comparative effect of statins has not been assessed.MethodsMEDLINE, Embase, and the Cochrane Central database were searched for randomized controlled trials that assessed statins in older patients.ResultsSeventeen trials were analyzed. When used for secondary prevention, statins were associated with reduced risk of cardiovascular events, all-cause mortality, cardiovascular mortality, revascularization, and stroke. When used for primary prevention, statins reduced the risk of myocardial infarction and revascularization, but did not significantly affect other outcomes. A modest difference between pharmaceutical statin products was found, and high-quality evidence indicated that intensive atorvastatin had the greatest benefits for secondary prevention.ConclusionsIn secondary prevention, evidence strongly suggests that statins are associated with a reduction in the risk of all-cause mortality, cardiovascular events, cardiovascular mortality, and revascularization. However, differences in the effects of various statins do not appear to have significant effects on therapy in secondary prevention for the elderly.

Spotlight on the January 16 issue

#### Notable in Neurology This Week This issue features an article that describes the neuroprotective and compensatory effects of intellectual activity on brain aging and cognition during amyloid accumulation and another that discusses the brain amyloid pathology in a population at risk of dementia, but with normal cognition. A featured Special Article details an update of the 2001 American Academy of Neurology guideline on mild cognitive impairment. ### Comparative effect of statins on the risk of incident Alzheimer disease This observational study used head-to-head comparison to evaluate the possible neuroprotective effect of statins. Fungus-derived and lipophilic statins did not decrease …

THU0243 A Comparison of Fenofibrate and Simvastatin Anti-Inflammatory Effects in the Treatment of Rheumatoid Arthritis

BackgroundStatins have been demonstrated to reduce disease activity in rheumatoid arthritis (RA) patients. There is growing evidence that another class of hypolipidemic drugs – PPARalpha agonists, or fibrates, may play...

Comparative effects of statins on murine cardiac gene expression profiles in normal mice

Recent clinical data suggest that the efficacy of statin treatment in patients with heart failure varies depending on the drugs administered. The present study was undertaken to compare murine cardiac gene expression profiles following treatment with four different statins. In normal male C57BL/6J mice, 4 weeks of treatment with or without a statin (pitavastatin, pravastatin, rosuvastatin, or atorvastatin) did not affect any biochemical parameters, including the lipid profile. However, cardiac gene expression profiling by microarray analysis revealed distinct patterns among the five groups. Several genes that might be involved in cardiac function, including Ccnd2, Klf7 and Timp3, were differentially regulated by treatment with a specific statin. In the primary cultured neonatal mouse cardiomyocytes, statin-induced changes in the expression of these genes were largely unaffected by supplementation with mevalonic acid. These data indicate that statins directly regulate cardiac gene expression in a drug-specific manner in normal mice. Additional studies are needed to determine whether these differences influence the clinical efficacy in particular patients, such as those with heart failure.

Comparative effects of statins on major cerebrovascular events: a multiple-treatments meta-analysis of placebo-controlled and active-comparator trials

Statins are important in the prevention of major cerebrovascular events. Whether, and the extent to which, individual statins differ in terms of their effect on these outcomes has not been studied. The aim of this review was to evaluate the comparative effects of individual statins on major cerebrovascular events. We systematically reviewed 61 trials including 187 038 individuals with, or at risk of developing, cardiovascular disease. We performed pair-wise and multiple-treatments meta-analyses for major cerebrovascular events, in addition to fatal and non-fatal strokes separately. Across all populations, statins were significantly more effective than control in reducing major cerebrovascular events [odds ratio (OR): 0.82, 95% CI: 0.77, 0.87], with no differences among individual statins. Statins were also effective in patients with established cardiovascular disease (OR: 0.83, 95% CI: 0.75, 0.91) and in those without (OR: 0.80, 95% CI: 0.71, 0.91). Considering individual statins, significant risk reductions were achieved with atorvastatin (OR: 0.74, 95% CI: 0.63, 0.85), pravastatin (OR: 0.86, 95% CI: 0.76, 0.97) and simvastatin (OR: 0.75, 95% CI: 0.62, 0.88) as compared with control on major cerebrovascular events across all populations. Statins led to significant reductions in the risk of non-fatal strokes (OR: 0.77, 95% CI: 0.71, 0.85) but not of fatal strokes (OR: 0.96, 95% CI: 0.80, 1.15). Findings were not sensitive to dose differentials of individual statins across the trials. No significant heterogeneity or inconsistency was detected. Statins significantly reduce the incidence of major cerebrovascular events as compared with control. Our analysis provided evidence to confirm the class effect of statins in preventing major cerebrovascular events.

820-1 Comparative effects of statins on atherogenic dyslipidemia in patients with the metabolic syndrome

820-1 Comparative effects of statins on atherogenic dyslipidemia in patients with the metabolic syndrome